![PolarityTE Stock Quote](https://g.foolcdn.com/art/companylogos/mark/PTE.png)
PolarityTE (NASDAQ: PTE)
PolarityTE Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
PolarityTE Company Info
PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.
News & Analysis
Is Co-Diagnostics Stock a Buy?
The company's stock had a huge week after announcing that Arches Research has signed a deal to use its coronavirus test kit.
Why PolarityTE Is Sinking Today
Shares drop after the company announces that it is raising capital. Here are the must-know details for investors.
Why PolarityTE Stock Tanked Today
Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.
Why PolarityTE Stock Is Shooting Higher Today
Traders cheered after some positive regulatory news emerged.
Here's Why PolarityTE Got Crushed Today
The tiny biopharma found itself in the crosshairs of infamous short-seller Citron Research.
Why Nabors Industries, PolarityTE, and Evolus Slumped Today
Find out which of these stocks got criticism from a famous short-seller.
Here's Why PolarityTE Dropped as Much as 13.1% Today
The biopharma announced the pricing of a stock offering, but something seems off with this company.
5 Reasons Not to Worry This Week
Not every company is heading the wrong way on the bottom line this week.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.